annual CFF:
-$4.19B-$2.43B(-138.38%)Summary
- As of today (August 17, 2025), TAK annual cash flow from financing activities is -$4.19 billion, with the most recent change of -$2.43 billion (-138.38%) on March 1, 2025.
- During the last 3 years, TAK annual CFF has risen by +$4.37 billion (+51.08%).
- TAK annual CFF is now -115.58% below its all-time high of $26.88 billion, reached on March 31, 2019.
Performance
TAK Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$1.49B+$499.47M(+25.16%)Summary
- As of today (August 17, 2025), TAK quarterly cash flow from financing activities is -$1.49 billion, with the most recent change of +$499.47 million (+25.16%) on June 1, 2025.
- Over the past year, TAK quarterly CFF has dropped by -$3.52 billion (-173.22%).
- TAK quarterly CFF is now -110.58% below its all-time high of $14.05 billion, reached on March 31, 2019.
Performance
TAK quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$8.45B-$3.52B(-71.26%)Summary
- As of today (August 17, 2025), TAK TTM cash flow from financing activities is -$8.45 billion, with the most recent change of -$3.52 billion (-71.26%) on June 1, 2025.
- Over the past year, TAK TTM CFF has dropped by -$8.44 billion (-154125.27%).
- TAK TTM CFF is now -131.79% below its all-time high of $26.58 billion, reached on March 31, 2019.
Performance
TAK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TAK Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -138.4% | -173.2% | -10000.0% |
| 3 y3 years | +51.1% | +10.7% | -13.5% |
| 5 y5 years | +48.1% | +17.1% | +10.3% |
TAK Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -138.4% | +51.1% | -173.2% | +65.7% | -2853.6% | at low |
| 5 y | 5-year | -138.4% | +54.7% | -173.2% | +65.7% | -2853.6% | +31.4% |
| alltime | all time | -115.6% | +54.7% | -110.6% | +75.0% | -131.8% | +31.4% |
TAK Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$1.49B(-25.2%) | -$8.45B(+71.3%) |
| Mar 2025 | -$4.19B(+138.4%) | -$1.99B(-54.2%) | -$4.93B(+45.2%) |
| Dec 2024 | - | -$4.34B(+577.3%) | -$3.40B(-1207.4%) |
| Sep 2024 | - | -$640.38M(-131.6%) | $306.83M(-5700.9%) |
| Jun 2024 | - | $2.03B(-550.9%) | -$5.48M(-99.8%) |
| Mar 2024 | -$1.76B(-60.4%) | -$450.06M(-28.8%) | -$2.46B(+8.0%) |
| Dec 2023 | - | -$632.25M(-33.6%) | -$2.27B(-51.5%) |
| Sep 2023 | - | -$952.69M(+126.3%) | -$4.69B(+17.0%) |
| Jun 2023 | - | -$421.06M(+56.9%) | -$4.01B(-23.7%) |
| Mar 2023 | -$4.43B(-48.2%) | -$268.38M(-91.2%) | -$5.25B(-27.5%) |
| Dec 2022 | - | -$3.05B(+1018.9%) | -$7.25B(+32.0%) |
| Sep 2022 | - | -$272.26M(-83.6%) | -$5.49B(-26.3%) |
| Jun 2022 | - | -$1.66B(-26.4%) | -$7.44B(-21.9%) |
| Mar 2022 | -$8.56B(-7.4%) | -$2.26B(+75.7%) | -$9.53B(-10.6%) |
| Dec 2021 | - | -$1.29B(-42.1%) | -$10.66B(-13.4%) |
| Sep 2021 | - | -$2.23B(-40.7%) | -$12.31B(+0.6%) |
| Jun 2021 | - | -$3.76B(+10.8%) | -$12.23B(+19.1%) |
| Mar 2021 | -$9.25B(+14.5%) | -$3.39B(+15.4%) | -$10.27B(+25.1%) |
| Dec 2020 | - | -$2.94B(+36.6%) | -$8.21B(+46.0%) |
| Sep 2020 | - | -$2.15B(+20.0%) | -$5.62B(-40.3%) |
| Jun 2020 | - | -$1.79B(+34.9%) | -$9.42B(+1.9%) |
| Mar 2020 | -$8.08B(-130.0%) | -$1.33B(+275.8%) | -$9.25B(-250.9%) |
| Dec 2019 | - | -$353.41M(-94.1%) | $6.13B(-69.2%) |
| Sep 2019 | - | -$5.95B(+268.0%) | $19.88B(-22.7%) |
| Jun 2019 | - | -$1.62B(-111.5%) | $25.71B(-3.2%) |
| Mar 2019 | $26.88B(-1037.4%) | $14.05B(+4.9%) | $26.58B(+138.5%) |
| Dec 2018 | - | $13.40B(<-9900.0%) | $11.14B(-492.1%) |
| Sep 2018 | - | -$118.49M(-84.3%) | -$2.84B(-2.3%) |
| Jun 2018 | - | -$753.32M(-45.6%) | -$2.91B(-1.3%) |
| Mar 2018 | -$2.87B(-204.6%) | -$1.38B(+136.2%) | -$2.94B(-453.9%) |
| Dec 2017 | - | -$585.80M(+217.7%) | $831.87M(+11.3%) |
| Sep 2017 | - | -$184.37M(-76.7%) | $747.52M(-12.0%) |
| Jun 2017 | - | -$790.50M(-133.0%) | $849.16M(-68.3%) |
| Mar 2017 | $2.74B(-374.5%) | $2.39B(-457.0%) | $2.68B(+355.5%) |
| Dec 2016 | - | -$670.16M(+710.0%) | $588.57M(-18.5%) |
| Sep 2016 | - | -$82.73M(-107.9%) | $722.47M(+1.1%) |
| Jun 2016 | - | $1.04B(+246.5%) | $714.37M(-168.7%) |
| Mar 2016 | -$998.88M | $300.42M(-156.0%) | -$1.04B(-60.2%) |
| Dec 2015 | - | -$536.25M(+490.3%) | -$2.61B(+3.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$90.84M(-87.3%) | -$2.54B(-5.7%) |
| Jun 2015 | - | -$713.66M(-43.9%) | -$2.69B(-2.3%) |
| Mar 2015 | -$2.59B(-355.9%) | -$1.27B(+177.8%) | -$2.75B(+71.5%) |
| Dec 2014 | - | -$458.27M(+87.0%) | -$1.60B(-11.3%) |
| Sep 2014 | - | -$245.10M(-68.4%) | -$1.81B(-316.6%) |
| Jun 2014 | - | -$775.89M(+519.5%) | $834.97M(-13.3%) |
| Mar 2014 | $1.01B(-155.2%) | -$125.25M(-81.1%) | $963.50M(-11.5%) |
| Dec 2013 | - | -$662.29M(-127.6%) | $1.09B(-37.8%) |
| Sep 2013 | - | $2.40B(-470.5%) | $1.75B(-370.5%) |
| Jun 2013 | - | -$647.36M(+1354.6%) | -$647.36M(-62.0%) |
| Mar 2013 | -$1.84B(-136.8%) | - | - |
| Mar 2012 | $4.99B(-391.4%) | - | - |
| Mar 2011 | -$1.71B(+7.3%) | -$44.50M(-94.5%) | -$1.70B(-1.6%) |
| Dec 2010 | - | -$807.49M(+412.8%) | -$1.73B(+4.6%) |
| Sep 2010 | - | -$157.47M(-77.3%) | -$1.65B(+2.2%) |
| Jun 2010 | - | -$692.50M(+868.4%) | -$1.62B(+1.4%) |
| Mar 2010 | -$1.59B(-62.3%) | -$71.51M(-90.2%) | -$1.60B(+4.7%) |
| Dec 2009 | - | -$731.82M(+497.4%) | -$1.52B(+92.4%) |
| Sep 2009 | - | -$122.50M(-81.7%) | -$792.25M(+18.3%) |
| Jun 2009 | - | -$669.75M | -$669.75M |
| Mar 2009 | -$4.23B(+84.6%) | - | - |
| Mar 2008 | -$2.29B(-15.1%) | - | - |
| Mar 2007 | -$2.70B(+242.6%) | - | - |
| Mar 2006 | -$788.85M(+14.7%) | - | - |
| Mar 2005 | -$687.62M(+30.9%) | - | - |
| Mar 2004 | -$525.17M(+8.5%) | - | - |
| Mar 2003 | -$483.93M(+14.8%) | - | - |
| Mar 2002 | -$421.40M(+11.2%) | - | - |
| Mar 2001 | -$378.99M(+51.2%) | - | - |
| Mar 2000 | -$250.60M(+39.2%) | - | - |
| Mar 1999 | -$180.07M(+12.7%) | - | - |
| Mar 1998 | -$159.73M(+18.6%) | - | - |
| Mar 1997 | -$134.69M(-16.4%) | - | - |
| Mar 1996 | -$161.04M(-40.9%) | - | - |
| Mar 1995 | -$272.59M(+100.6%) | - | - |
| Mar 1994 | -$135.89M(+83.5%) | - | - |
| Mar 1993 | -$74.07M(-18.5%) | - | - |
| Mar 1992 | -$90.92M(+16.4%) | - | - |
| Mar 1991 | -$78.11M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash flow from financing activities?
- What is the all time high annual CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual CFF year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly CFF year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM CFF year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash flow from financing activities?
The current annual CFF of TAK is -$4.19B
What is the all time high annual CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash flow from financing activities is $26.88B
What is Takeda Pharmaceutical Company Limited annual CFF year-on-year change?
Over the past year, TAK annual cash flow from financing activities has changed by -$2.43B (-138.38%)
What is Takeda Pharmaceutical Company Limited quarterly cash flow from financing activities?
The current quarterly CFF of TAK is -$1.49B
What is the all time high quarterly CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash flow from financing activities is $14.05B
What is Takeda Pharmaceutical Company Limited quarterly CFF year-on-year change?
Over the past year, TAK quarterly cash flow from financing activities has changed by -$3.52B (-173.22%)
What is Takeda Pharmaceutical Company Limited TTM cash flow from financing activities?
The current TTM CFF of TAK is -$8.45B
What is the all time high TTM CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM cash flow from financing activities is $26.58B
What is Takeda Pharmaceutical Company Limited TTM CFF year-on-year change?
Over the past year, TAK TTM cash flow from financing activities has changed by -$8.44B (-154125.27%)